Valerio Therapeutics is a clinical-stage biotechnology company based in France and in the US that develops new cancer drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). 

DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. 

The Company focuses on the development of first-in-class compounds from preclinical (translational) research to human clinical proof-of-concept studies. It thus leads its programs to the most value-creating and attractive inflection points for potential partners. 

The Company's portfolio is based on platON™, Valerio Therapeutic's decoy oligonucleotide platform. 

PlatON™ is intended to generate new compounds based on an unparalleled DDR decoy mechanism and capitalizing on the expertise the Company has developed on this type of oligonucleotides. 

The Company's portfolio includes: 
-	AsiDNA™, a first-in-class product interfering with tumor DNA break repair, based on a decoy agonist mechanism, unmatched in the DDR field, which could, among other things, combat tumor resistance. AsiDNA™ is in clinical development in several trials, in combination with PARP inhibitors or in combination with radiation therapy. 
-	A new family of compounds, OX400, positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. The first molecule identified, OX401, is currently being optimized in a preclinical phase.

The Company is convinced of the significant therapeutic potential of its decoy oligonucleotide technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer treatment.

Biotechnology

Medical Devices

Valerio Therapeutics

Valerio Therapeutics' headquarters in Paris, France

De La Montagne

Dominique Costantini

Audrey Legentil-Duméry

Allison Marks

Lucile Dez

Assad Hamza

David Carp

The Research and Development team at Valerio Therapeutics focuses on advancing innovative cancer drug candidates through rigorous preclinical and clinical research. This team conducts thorough investigations into DNA Damage Response mechanisms, leveraging the unique decoy oligonucleotide platform, platON™, to design and optimize first-in-class compounds like AsiDNA™ and OX401. Their work aims to generate novel therapeutic strategies that enhance the effectiveness of cancer treatments and address tumor resistance, ultimately bringing groundbreaking therapies to clinical proof-of-concept stages.

Research and Development

This department oversees the governance practices and strategic direction of the organization through board leadership.

Board Governance

This department oversees all aspects of chemistry operations and research within the organization.

Chemistry Department

The Clinical Development team at Valerio Therapeutics plays a crucial role in advancing the company’s innovative cancer drug candidates from preclinical stages to human clinical trials. This team oversees the design, execution, and management of clinical studies, ensuring compliance with regulatory standards while evaluating the safety and efficacy of compounds like AsiDNA™ and OX401. By collaborating with cross-functional partners, they aim to generate robust clinical data that supports strategic decision-making and fosters partnerships for future development.

Clinical Development

This department focuses on biological research and cellular biology expertise.

Biology Research

The Clinical Research and Development team at Valerio Therapeutics is responsible for advancing innovative cancer therapies through rigorous clinical trials and preclinical studies. This multidisciplinary team collaborates on the design and execution of trials for compounds like AsiDNA™ and OX400, ensuring compliance with regulatory standards while contributing to the strategic direction of drug development. Their expertise spans drug discovery, regulatory affairs, quality assurance, and oligonucleotide chemistry, ultimately aiming to demonstrate the efficacy and safety of novel therapies and drive them towards successful commercialization.

Valerio Therapeutics

Org chart

Teams

Research and Development

Board Governance

Chemistry Department

Clinical Development

Biology Research

Clinical Research and Development

Offices

Valerio Therapeutics

Org chart

Teams

Research and Development

Board Governance

Chemistry Department

Clinical Development

Biology Research

Clinical Research and Development

Offices

Related companies